Previous Article | Next Article 
Molecular and Cellular Biology, November 2001, p. 7807-7816, Vol. 21, No. 22
0270-7306/01/$04.00+0 DOI: 10.1128/MCB.21.22.7807-7816.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Specific Double-Stranded RNA Interference in
Undifferentiated Mouse Embryonic Stem Cells
Shicheng
Yang,1
Stephen
Tutton,1
Eric
Pierce,2 and
Kyonggeun
Yoon1,*
Department of Dermatology and Cutaneous
Biology and Department of Biochemistry and Molecular Pharmacology,
Jefferson Institute of Molecular Medicine, Thomas Jefferson University,
and Jefferson Medical College,1 and
F. M. Kirby Center for Molecular Ophthalmology, Scheie Eye
Institute, University of Pennsylvania School of
Medicine,2 Philadelphia, Pennsylvania
Received 18 April 2001/Returned for modification 4 June
2001/Accepted 16 August 2001
 |
ABSTRACT |
Specific mRNA degradation mediated by double-stranded RNA (dsRNA)
interference (RNAi) is a powerful way of suppressing gene expression in
plants, nematodes, and fungal, insect, and protozoan systems. However,
only a few cases of RNAi have been reported in mammalian systems. Here,
we investigated the feasibility of the RNAi strategy in several
mammalian cells by using the enhanced green fluorescent protein gene as
a target, either by in situ production of dsRNA from transient
transfection of a plasmid harboring a 547-bp inverted repeat or by
direct transfection of dsRNA made by in vitro transcription. Several
mammalian cells including differentiated embryonic stem (ES) cells did
not exhibit specific RNAi in transient transfection. This long dsRNA,
however, was capable of inducing a sequence-specific RNAi for the
episomal and chromosomal target gene in undifferentiated ES cells.
dsRNA at 8.3 nM decreased the cognate gene expression up to 70%.
However, RNAi activity was not permanent because it was more pronounced
in early time points and diminished 5 days after transfection. Thus,
undifferentiated ES cells may lack the interferon response, similar to
mouse embryos and oocytes. Regardless of their apparent RNAi activity,
however, cytoplasmic extracts from mammalian cells produced a small RNA of 21 to 22 nucleotides from the long dsRNA. Our results suggest that
mammalian cells may possess RNAi activity but nonspecific activation of
the interferon response by longer dsRNA may mask the specific RNAi. The
findings offer an opportunity to use dsRNA for inhibition of gene
expression in ES cells to study differentiation.
 |
INTRODUCTION |
Frequently, inhibition of gene
expression has been caused not only by antisense mRNA but also, in some
cases, by expression of sense mRNA which has been used as a control.
Moreover, this gene silencing by sense mRNA was shown to be sequence
specific for the homologous gene. These initially confusing
observations have now been attributed to gene silencing by the
production of a minute amount of double-stranded RNA (dsRNA) generated
by transcription of the sense mRNA by its promoter and the antisense
mRNA by a cryptic promoter within the construct (reviewed in references 3, 6, 11, 26, 27, and 33). The term RNA
interference (RNAi) was defined after the discovery that injection of
dsRNA into the nematode Caenorhabditis elegans led to
specific silencing of the gene homologous to the delivered RNA
(12). RNAi was also observed in fruit flies, zebra fish,
and other animals, including mice (7, 17, 30, 34, 35). The
posttranscriptional gene silencing of C. elegans (18,
19, 28) is closely linked to the mechanism of cosuppression in
plants and quelling in fungi (14, 21-23, 29).
Unlike other organisms, accumulation of very small amounts of dsRNA in
mammalian cells results in the interferon response. This leads to an
overall block of translation by inactivation of an elongation factor by
protein kinase. In addition, dsRNA activates a latent
2',5'-oligoadenylate synthase and increases synthesis of a
2',5'-oligonucleotide, causing activation of RNase L and nonspecific
mRNA degradation. These events result in the onset of apoptosis in
mammalian cells (13, 16). The natural function of RNAi and
cosuppression appears to be protection of the host genome against
invasion by mobile genetic elements such as transposons and viruses,
which produce dsRNA in host cells (14, 18, 20, 27). Such
considerations have discouraged investigators from using RNAi in
mammals. Recently, however, RNAi has been reported in several mammalian
systems. Transfection of a plasmid carrying the full-length pro-
1(I)
collagen gene into rodent fibroblasts decreased the endogenous
pro-
1(I) collagen mRNA up to 90% (1). RNAi activity
was also reported in CHO cells, although the amount of dsRNA required
for interference was 2,500 times more than in Drosophila S2
cells (32). Sequence-specific RNAi has been demonstrated
in the preimplantation mouse embryo and oocytes by direct injection of
dsRNA (30, 35). When dsRNA corresponding to an active
green fluorescent protein (GFP) gene was injected into mouse zygotes,
dsRNAi was effective throughout the blastocyst stage and implantation
until embryos reached 6.5 days of development, corresponding to a 40- to 50-fold increase in cell mass (35). With these
findings, it becomes critical to determine whether RNAi can be applied
in mammalian tissue culture for gene silencing.
The hallmark of RNAi is its specificity. The dsRNA triggers a specific
degradation of homologous mRNA only within the region of identity with
the dsRNA (37). The ability of a few molecules of dsRNA to
eliminate a much larger pool of endogenous mRNA suggests a catalytic or
amplification component to the RNAi mechanism. Results from studies of
RNAi in plants suggested a mechanism, in which an RNA-primed RNA
polymerase can spread gene silencing by dsRNA (28).
Another model involves a catalytic RNA degradation generated by the
dsRNA molecule and as yet unknown protein components. Recently, dsRNAs
were shown to be processed to small 21- to 22-bp sizes in
Drosophila embryo extracts (10, 36, 37),
cultured S2 cells (2, 15), and C. elegans (24), making it likely that such RNAs
serve as the specificity determinants in the RNAi reaction. These
results suggest that dsRNA molecules are initially activated by a
process that does not require interactions with their cognate mRNA
target. Activation would appear to be a limiting step in RNAi, as the
reaction is saturated at relatively low levels of dsRNA in vivo
(12), potentiated by preincubation with dsRNA (31), and inhibited by excess unrelated dsRNAs
(36).
Here, we investigated the feasibility of the RNAi strategy for gene
silencing in several mammalian cell lines by using the enhanced GFP
(EGFP) gene as a target. Our results show that undifferentiated mouse
embryonic stem (ES) cells exhibit a sequence-specific RNAi at a dsRNA
concentration similar to that needed in Drosophila S2
cells.We also compared the ability of different mammalian cell types to
degrade dsRNA into small pieces of 21 to 22 bp, which is the initial
step on RNAi activity.
 |
MATERIALS AND METHODS |
Plasmids.
With pEGFP-C1 (Clontech, Palo Alto, Calif.) as the
template, a 547-bp fragment encoding a portion of the EGFP gene
beginning from the ATG start codon was amplified by PCR with the
primers 5'-GCC GTC GAC GGT ACC TCT AGA ACG CGT GCC ATG GTG AGC AAG
GGC GAG GAG-3' and 5'-GCC GCG GCC GCG GCC CTA TTA GCC CTC
GAG TAC ATG GTC GGC GAG CTG CAC GCT-3'. A set of restriction
sites, SalI, XbaI, and
MluI at the 5' end and EcoRI and
NotI at the 3' end, were incorporated in each primer.
After PCR amplification, the 547-bp fragment was digested with
NotI and self-ligated. The dimer of the 547-bp fragment
was isolated from the agarose gel, purified, ligated to the pGEMT Easy
vector (Promega, Madison, Wis.), and used to transform
Escherichia coli DH5
(Gibco-BRL, Rockville, Md.)
competent cells. The resulting colonies were screened for inverted
repeats by restriction enzyme analysis. The sequence of the plasmid
harboring an inverted repeat (pGEMT-dsEGFP) was confirmed by DNA sequencing.
To generate control dsRNA, a 629-bp fragment encoding a portion of the
lacZ gene (nucleotides 1331 to 1960 from the AUG start codon) was amplified by PCR and ligated to the pGEMT Easy vector. The
colonies were screened for plasmids containing the insert in the sense
and antisense orientations. The plasmid pSC6-T7-Neo, encoding the T7
RNA polymerase gene under the control of the cytomegalovirus (CMV)
promoter was a generous gift from M. Billeter (25). The pActin-lacZ and pIZ/US9-GFP plasmids, encoding the lacZ and
EGFP genes under the control of the Drosophila promoters for
actin and OpIE2, respectively, were generous gifts from Gregory Hannon. The pCMV-lacZ plasmid was purchased from Clontech.
In vitro transcription of dsRNA.
The pGEMT-dsEGFP construct
with an inverted repeat containing a portion of the EGFP gene was
linearized with PstI at a unique site located at the 3' end
of the inverted repeat. Using the RiboMax large-scale RNA production
system-T7 (Promega, Madison, Wis.), the transcription reaction was
performed at 37°C for 3 h, according to the manufacturer's specifications.
Radiolabeled dsRNA was generated by incorporation of
[

-
32P]UTP during in vitro transcription.
After performing the in vitro
transcription reaction, RNase-free DNase
(Promega, Madison, Wis.)
was added to the reaction mixture at 1 U/µg
of the template DNA
and incubated for 15 min at 37°C. The transcript
was further purified
by extraction in phenol-chloroform-isoamyl alcohol
(25:24:1) and
ethanol precipitation. The pellet was washed with 70%
ethanol,
dried at room temperature, and resuspended in TE buffer (10 mM
Tris [pH 7.5] and 1 mM EDTA). To determine the folded structure
of
the dsRNA, an aliquot of the RNA sample was digested using
a mixture of
RNase A and T
1 (Ambion, Austin, Tex.) at 37°C
for
30 min and analyzed on 5% nondenaturing and denaturing
polyacrylamide
gels containing 40% formamide and 7 M urea. For dsRNA
of the
lacZ gene, plasmid containing either the sense or
antisense
lacZ fragment
was linearized by restriction enzyme
SalI, located downstream
of the multiple cloning site. The
sense and antisense RNAs were
generated separately by in vitro
transcription and annealed to
generate a 740-bp dsRNA
fragment.
Cell culture.
Drosophila S2 cells (generous gift
from G. J. Hannon) were maintained at 27°C in 90% Schneider's
insect medium (Gibco-BRL, Rockville, Md.) and 10% heat-inactivated
fetal bovine serum (FBS). Cells were split every 2 to 3 days to
maintain exponential growth. BsrT7/5 (4), a derivative of
BHK-21 cells that express the T7 RNA polymerase (generous gift from M. Schnell), were maintained in Dulbecco's modified Eagle's medium
(DMEM) supplemented with 10% FBS and penicillin-streptomycin. CHO-K1
cells were maintained in F-12 medium with 10% heat-inactivated FBS.
Mouse embryonic stem (ES) cells AB2.2 (Stratagene, La Jolla, Calif.)
were maintained in DMEM supplemented with 1,250 U of leukemia
inhibitory factor (LIF) (Chemicon, Temecula, Calif.) per ml 15% FBS, 2 mM glutamine, 100 mM
-mercaptoethanol, and 1× nonessential amino
acids. Mouse embryonic fibroblast STO cells (American Type Culture
Collection, Rockville, Md.) were grown in DMEM with 10% FBS. The STO
feeder cells were plated on dishes coated with 0.1% (wt/vol) gelatin, treated with mitomycin C (Sigma, St. Louis, Mo.) at a concentration of
10 µg/ml for 2.5 h at 37°C, and washed three times with
phosphate-buffered saline (PBS). ES AB2.2 cells were plated onto
mitomycin C-treated STO feeder cells and passaged every 2 days with a
daily change of culture medium. For all experiments, ES cells were kept
between 17 and 19 passages, counted from the time of isolation of ES
cells from the inner cell mass of the blastocysts.
Transfection.
The day before transfection, S2 cells were
plated in a 12-well plate (106 cells per well).
Various amounts of the PstI-linearized pGEMT-dsEGFP plasmid
or dsRNA generated by in vitro transcription were combined with 1 µg
of the target plasmid encoding EGFP (pEGFP-C1) and 1 µg of the
plasmid encoding the T7 RNA polymerase (pSC6-T7-Neo). In all
transfection experiments, a constant amount of total DNA, 5 µg, was
maintained by addition of the unrelated pUC19 plasmid. DNA was
transfected to S2 cells by the calcium phosphate method. The plasmid
encoding
-galactosidase, pCMV-lacZ, was used as a control. CHO-K1
and STO feeder cells were plated in a 12-well plate
(105 cells per well) the day before transfection.
Various amounts of the PstI-linearized pGEMT-dsEGFP plasmid
or in vitro-transcribed dsRNA was combined with 1 µg of the target
plasmid encoding EGFP (pEGFP-C1) and 1 µg of the plasmid encoding the
T7 RNA polymerase (pSC6-T7-Neo). The DNA mixture was transfected to
cells by addition of 7.5 µg of Lipofectamine (Gibco-BRL, Rockville,
Md.). The same transfection protocol was used for BsrT7/5 cells except
the pSC6-T7-Neo plasmid was not added, as BsrT7/5 already expresses the
T7 RNA polymerase (4).
ES cells were grown on feeder STO cells, trypsinized for 5 min, and
pipetted extensively to prevent clumping of cells. After
addition of 5 volumes of ES medium, cells were put back in the
incubator for 45 min.
The majority of the STO cells adhere to
the plate during this
incubation, and ES cells were harvested
from the suspension. Various
amounts of the
PstI-linearized pGEMT-dsEGFP
plasmid or dsRNA
were combined with 1 µg of the target plasmid
encoding EGFP
(pEGFP-C1) and 1 µg of the plasmid encoding the
T7 RNA polymerase
(pSC6-T7-Neo). In all transfection experiments,
a constant amount of
total DNA, 5 µg, was maintained by addition
of the unrelated pUC19
plasmid. A 150-µg M9 peptide (generous
gift from Scott Diamond) was
then added to the DNA solution in
100 µl of OptiMEM, and the DNA-M9
mixture was further incubated
for 15 min at room temperature.
Lipofectamine (7.5 µg) was diluted
in 100 µl of OptiMEM and added
to the DNA-M9 mixture for 45 min.
The DNA-M9-Lipofectamine mixture was
added to 3 × 10
5 ES cells in suspension and
plated in a 12-well gelatin-coated
plate containing 3 × 10
5 STO feeder cells pretreated with mitomycin C
(Sigma, St. Louis,
Mo.). The same procedure was used for transfection
of ES cells
without feeders except that ES cells were plated directly
on gelatin
plates without STO feeder cells, using medium without LIF .
Quantitation of EGFP and
-galactosidase activities.
All
adherent cells were harvested 72 h after transfection by washing
with PBS and scraping cells into 100 µl of ice-cold lysate buffer
(91.5 mM K2HPO4, 85 mM
KH2PO4, and 1 mM
dithiothreitol [DTT]). The harvested cells were then subjected to a
dry-ice/ethanol freezing and thawing at 37°C for three cycles and
centrifuged at 12,000 rpm for 5 min at 4°C. The supernatant was
stored at
70°C until use. For ES cells with feeders, 72 h
after transfection, cells were trypsinized for 5 min and pipetted
extensively. After addition of 5 volumes of ES medium, cells were put
back in the incubator for 45 min to allow the STO cells to attach to
the plate. After this procedure, ES cells constituted more than 95% of
the cells in suspension. ES cells were transferred to a tube,
centrifuged, and processed the same way as other cells. The protein
concentration of cell lysates was measured with the Pierce reagent
(Pierce, Rockford, Ill.) in a 96-well plate. For each lysate, the same amount of protein was used for the fluorescence and chemiluminescence measurements. Fluorescence was measured in relative light units (RLUs)
using a 96-well black flat-bottomed plate (Corning Costar, Cambridge,
Mass.) and an FL 600 microplate reader (Bio-Tek Instrument, Winooski,
Vt.) with KC4 data reduction software on an external personal computer,
which controls the reader function and data capture. Excitation was at
485 nm with a 20-nm band-pass filter, and emission was at 530 nm with a
25-nm band-pass filter. To account for the background, each
fluorescence reading was subtracted from that of the untransfected cell
lysate. The fluorescence reading of each lysate was normalized to that
of the lysate prepared from cells transfected without dsRNA, either
pGEMT-dsEGFP plasmid or in vitro-transcribed dsRNA.

-Galactosidase activity was measured by histochemical staining and
chemiluminescence. Cells were fixed with 1% glutaraldehyde
and stained
with X-Gal staining solution [0.1 M sodium phosphate
(pH 8.0), 1.3 mM
MgCl
2, 3 mM
K
4Fe(CN)
6, 3 mM
K
3Fe(CN)
6, and 0.4
mg of
X-Gal (5-bromo-4-chloro-3-indolyl-

-
D-galactopyranoside)
in
N,
N-dimethyl formamide] for 4 h. For
chemiluminescence measurements,
cell lysates were prepared using the
Luminescent

-Galactosidase
Genetic Reporter System II kit (Clontech,
Palo Alto, Calif.).
Lysates were analyzed in triplicate by
chemiluminescence using
the Lumat LB 9507 luminometer (EG&G Berthold,
Bad Wildbad, Germany).
To account for the background, the
chemiluminescence reading was
subtracted from that of the untransfected
cell lysate. The RLUs
of each lysate were normalized to that of the
lysate prepared
from cells transfected without dsRNA, either
pGEMT-dsEGFP plasmid
or in vitro-transcribed
dsRNA.
Fluorescence microscopy of S2 and ES cells.
For fluorescence
microscopy, S2 cells (2 × 106 S2 cells/well
of a six-well plate) were plated and transfected with 2.5 µg of pIZ/US9-GFP and an increasing amount, 0, 1.5, or 3.0 µg, of the in
vitro-transcribed dsRNA by the calcium phosphate method. ES cells
(6 × 105 cells/well of a six-well plate)
were mixed with 2.5 µg of pEGFP-C1 plasmid and increasing amounts, 0, 1, and 2 µg, of the in vitro-transcribed dsRNA and plated on the STO
feeder cells as described above. Fluorescence micrographs were taken
72 h after transfection.
Analysis of RNA by Northern blotting in ES cells.
ES cells
were transfected by three plasmids as described above. Total RNA was
purified by the RNAeasy Mini kit (Qiagen, Valencia, Calif.) and
quantitated by UV absorbance at 260 nm. A total of 25 µg of RNA was
loaded into each lane in a 0.8% formaldehyde denaturing agarose gel,
and the Northern blotting was performed using the NorthernMax kit
(Ambion, Austin, Tex.). The EGFP probe was a 0.7-kb fragment generated
by NheI and BglII restriction enzyme digestions
of plasmid pEGFP-C1, and the lacZ probe was a 2.5 kb
fragment prepared by PvuII digestion of the pCMV-lacZ plasmid. The probes were labeled by
[
-32P]dCTP using the Megaprime DNA labeling
system (Amersham, Piscataway, N.J.). A cDNA probe corresponding to the
mouse
-actin coding sequence was hybridized as a control.
Generation of ES cells with integrated EGFP gene, transfection
with dsRNA, and FACS analysis.
To produce ES cells with an
integrated EGFP transgene, 2.5 × 106 AB2.2
cells were transfected with 6 µg of linearized pcDNA3-EGFP by M9
lipofection. G418 (275 µg/ml) selection was started 24 h after
transfection. After 10 days of selection with G418, the surviving ES
colonies were examined by fluorescence microscopy. Fluorescent colonies
were picked and expanded according to established techniques. The
number of integrated copies of pcDNA3-EGFP was determined by Southern
blot analysis using the EGFP coding region as a probe. Several ES
clones with a single copy of the EGFP gene were chosen for use in this
study. ES cells were seeded at 105 cells/well of
six-well plate in the presence and absence of the feeder layer and
transfected with 3 µg of in vitro-transcribed dsRNA-EGFP or
dsRNA-lacZ using 1.5 µg of Lipofectamine 2000 (Gibco-BRL, Rockville,
Md.). The transfected cells were maintained with daily changes of
medium and harvested at various time points to measure GFP
fluorescence. Cells were trypsinized, centrifuged, suspended in chilled
PBS, and subjected to fluorescence-activated cell sorting (FACS)
analysis using a FACScan flow cytometer (Becton Dickinson, San Jose,
Calif.). Instrument settings were adjusted to separate live from dead
cells, and fluorescence intensity data for 20,000 live cells were
collected for each experimental time point. The relative levels of
fluorescence for different samples were compared using the geometric
means. Instrument settings were kept constant for all samples within
each experiment. Data were analyzed using Cell Quest Software (Becton Dickinson).
Generation of small RNA fragments from dsRNA.
Cytoplasmic
extracts were isolated as described previously (8).
Extracts were prepared from cells in the log phase of growth, and
cytoplasmic proteins were extracted in a buffer containing 10 mM HEPES
(pH 7.9), 1.5 mM MgCl2, 10 mM KCl, 0.2 mM
phenylmethylsulfonyl fluoride (PMSF; Sigma, Saint Louis, Mo.), and 0.5 mM DTT (Sigma, Saint Louis, Mo.). The final dialysis was performed for
12 h in an excess volume of dialysis buffer (20 mM HEPES [pH
7.9], 20% glycerol, 100 mM KCl, 0.2 mM EDTA, 0.2 mM PMSF, and 0.5 mM
DTT). The protein concentration was measured by the Bradford assay. Cytoplasmic extracts (10 to 50 µg) were incubated with 30 nmol of
radiolabeled dsRNA for 1 h at 30°C for S2 cells or 37°C for mammalian cells. The standard reaction was carried out in a 20-µl reaction buffer containing 20 mM HEPES, 2 mM magnesium acetate, 2 mM
DTT, 1 mM ATP, 40 mM creatine phosphate, and 100 µg of creatine phosphokinase and 1 U of RNasin (Ambion, Austin, Tex.) per ml. After
the reaction, samples were treated with proteinase K (1 mg/ml)-0.5%
sodium dodecyl sulfate (SDS) and purified by phenol-chloroform extraction. The size of the dsRNA was examined by a 12% denaturing acrylamide gel. After completion of electrophoresis, the gel was stained with ethidium bromide. The gel was then fixed in a 30% methanol-7% acetic acid solution, dried, and exposed to X-ray film at
80°C.
 |
RESULTS |
Generation of dsRNA for EGFP gene.
To generate dsRNA in
mammalian cells in situ, we cloned an inverted repeat of a portion of
the EGFP gene, extending from the ATG codon to nucleotide 547, under
the control of the T7 RNA polymerase (pGEMT-dsEGFP). Using this
plasmid, we investigated the feasibility of the RNAi strategy for gene
silencing in several mammalian cells by using the EGFP gene as a
target. Two strategies were used: (i) in situ production of dsRNA by
transient transfection of three plasmids, the target plasmid encoding
the EGFP gene (pEGFP-C1), the plasmid harboring a 547-bp inverted
repeat of the EGFP gene under control of the T7 promoter
(pGEMT-dsEGFP), and the plasmid containing the T7 RNA polymerase cDNA
under the control of the CMV promoter (pSC6-T7-Neo) (Fig.
1A), and (ii) direct transfection of in
vitro-transcribed dsRNA (547 bp) and the target plasmid pEGFP-C1 (Fig.
1B).

View larger version (35K):
[in this window]
[in a new window]
|
FIG. 1.
Strategy for generation of dsRNA. (A) In situ production
of dsRNA of EGFP. An inverted repeat of EGFP, starting from the ATG
codon to nucleotide 547 in the coding region, was cloned into the pGEMT
vector under control of the T7 promoter (pGEMT-dsEGFP). RNAi activity
in mammalian cells was tested by transient transfection of three
plasmids, the target plasmid encoding the EGFP gene, the linearized
pGEMT-dsEGFP, and plasmid encoding the T7 RNA polymerase cDNA. (B)
Direct transfection of dsRNA made by in vitro transcription. Mammalian
cells were transfected with dsRNA and the target plasmid encoding the
EGFP gene to compare the RNAi activities between in situ production of
dsRNA and in vitro-transcribed dsRNA. The dsRNA-EGFP was made by in
vitro transcription using the T7 RNA polymerase and the linearized
pGEMT-dsEGFP plasmid. (C) Analysis of dsRNA-EGFP transcribed by the T7
RNA polymerase. The pGEMT-dsEGFP plasmid was linearized by
PstI, located at the 3' end of the inverted repeat, to
generate a runoff transcript by the T7 RNA polymerase. The transcribed
RNA was digested with a mixture of RNases A and T1. The RNA
was analyzed in a 5% nondenaturing acrylamide gel. Lane M, 100-bp
dsDNA ladder. Lanes 1 and 2 depict in vitro-transcribed RNA with and
without RNase treatment, respectively. Lanes 3 and 4 show a control
1.8-kb RNA provided in the RiboMax kit, with and without RNase
treatment, respectively. (D) The same RNA samples were electrophoresed
on a 5% denaturing acrylamide gel containing 40% formamide and 7 M
urea. (E) Analysis of the dsRNA-lacZ transcribed by the T7 RNA
polymerase. The sense and antisense RNAs were transcribed from the
plasmid linearized by SalI and annealed to make dsRNA.
Lanes 1 and 2 depict in vitro-transcribed antisense and sense RNAs, and
lane 3 depicts annealed dsRNA in a 1% agarose gel.
|
|
The production of dsRNA was confirmed by in vitro transcription of the
pGEMT-dsEGFP plasmid by the T7 RNA polymerase. Nondenaturing
gel
electrophoresis revealed a transcript of approximately 550
bp that did
not change in size appreciably upon RNase A and RNase
T
1 digestion, consistent with a double-stranded
structure (Fig.
1C). When the RNA was analyzed in a 5% denaturing
acrylamide gel
(7 M urea-40% formamide), as expected, the size of the
transcript
was twice that in the nondenaturing gel (Fig.
1D). Upon
RNase
digestion, the fragment migrated predominantly to 550 nucleotides
in denaturing conditions, indicating cleavage at the connecting
loop of
the folded dsRNA (Fig.
1D). These results confirm the
generation of the
547-bp dsRNA by transcription of the pGEMT-dsEGFP
plasmid. As a
control, dsRNA for
lacZ (740 bp) was generated by
annealing
the sense and antisense transcripts (Fig.
1E).
Sequence-specific gene silencing by production of dsRNA in situ in
S2 cells.
To investigate whether production of a dsRNA in situ by
pGEMT-dsEGFP plasmid is sufficient to induce RNAi, we transfected S2
cells with three plasmids: pEGFP-C1, pSC6-T7-Neo, and increasing amounts of pGEMT-dsEGFP. When this plasmid is cotransfected with the
gene encoding the T7 RNA polymerase under the control of the CMV
promoter, it is expected to make dsRNA of 547 bp in mammalian cells. To
test the specificity of RNAi, the plasmid encoding the
-galactosidase, pCMV-lacZ, was added instead of pEGFP-C1 in the control experiment, where all other reagents were kept the same.
Transfection of the pGEMT-dsEGFP plasmid showed a sequence-specific and
dose-dependent inhibition of EGFP expression (Fig.
2A). In contrast,

-galactosidase
expression was not affected
by addition of the pGEMT-dsEGFP plasmid,
demonstrating the sequence-specific
RNAi. The CMV promoter was not as
strong as the
Drosophila promoters
actin or OpIE2 in S2
cells (data not shown). However, a sufficient
amount of protein was
generated to measure the EGFP and

-galactosidase
activities. S2
cells were also used to compare the efficiency
between the in situ
production of dsRNA and the direct transfection
of dsRNA made by in
vitro transcription. Transfection of pIZ/US9-EGFP
(the plasmid encoding
EGFP under the control of the
Drosophila promoter OpIE2) and
an increasing amount of dsRNA, ranging from
0 to 3.0 µg, resulted in
sequence-specific and dose-dependent
inhibition of EGFP expression
(Fig.
2B). Again,

-galactosidase
expression was not affected by
dsRNA (Fig.
2C). These results
demonstrate that production of dsRNA in
situ by the pGEMT-dsEGFP
plasmid is sufficient to produce RNAi in S2
cells.

View larger version (49K):
[in this window]
[in a new window]
|
FIG. 2.
dsRNA produced a sequence-specific and dose-dependent
gene silencing in Drosophila S2 cells. (A) Inhibition of
EGFP expression by in situ production of dsRNA. S2 cells were
transfected with three plasmids, pEGFP-C1 (1 µg), pSC6-T7-Neo (1 µg), and an increasing amount of pGEMT-dsEGFP, ranging from 0.25 to 1 µg. Throughout all transfections, the total amount of DNA was held
constant by addition of unrelated pUC19 plasmid. To test the sequence
specificity of RNAi, 1 µg of the plasmid encoding
lacZ, pCMV-lacZ, was used instead of pEGFP-C1. The RLUs
of fluorescence or chemiluminescence were normalized to that of lysate
containing no pGEMT-dsEGFP plasmid. The relative activities of cells
transfected with pEGFP-C1 plasmid (solid bars) and pCMV-lacZ plasmid
(open bars) are shown. Standard deviation indicates the variation among
at least three separate transfection experiments performed in
duplicate. (B) Sequence-specific and dose-dependent inhibition of EGFP
by the in vitro-transcribed dsRNA. S2 cells were transfected with 2.5 µg of pIZ/US9-GFP plasmid and 0, 1.5, or 3.0 µg of the in
vitro-transcribed dsRNA-EGFP (lanes 1, 2, and 3, respectively) using a
calcium phosphate method. Photographs were taken 72 h later,
depicted by a bright field (upper panel) and a fluorescence micrograph
(lower panel). (C) -Galactosidase expression is not inhibited by
in-vitro transcribed dsRNA-EGFP. As a control, S2 cells were
transfected with 2.5 µg of pActin-lacZ and 0, 1.5, or 3.0 µg of the
in vitro-transcribed dsRNA-EGFP by a calcium phosphate method.
Histochemical staining was carried out 72 h later.
|
|
Several mammalian cells do not exhibit sequence-specific RNAi
activity.
We investigated the feasibility of the RNAi strategy for
gene silencing in several mammalian cells by using the EGFP gene as a
target and transient transfection of three plasmids, pEGFP-C1, pSC6-T7-Neo, and pGEMT-dsEGFP. For most experiments,
105 cells were plated on a 12-well plate and
transfected with 1 µg of pEGFP-C1, 1 µg of pSC6-T7-Neo, and an
increasing amount of pGEMT-dsEGFP, ranging from 0.25 to 2 µg. Because
BsrT7/5 cells already express the T7 RNA polymerase (4),
transfection was carried out under identical conditions except that the
pSC6-T7-Neo plasmid was omitted. Two cell lines, BsrT7/5 cells and
mouse fibroblasts (STO), showed a non-sequence-specific inhibition by
dsRNA, indicated by reduction of both EGFP and
-galactosidase
activities as increasing amounts of pGEMT-dsEGFP were added (Fig.
3A and 3B). The CHO-K1 cells did not
exhibit any inhibition by dsRNA in cognate (EGFP) or noncognate
-galactosidase genes (Fig. 3C). In all experiments, we detected no
apparent cytotoxicity, as measured by cell numbers and morphology (data
not shown).

View larger version (18K):
[in this window]
[in a new window]
|
FIG. 3.
Several mammalian cells do not show sequence-specific
RNAi activity. Three mammalian cell lines, BsrT7/5 (A), STO (B), and
CHO-K1 (C), were tested for RNAi activity by transient transfection of
three plasmids, pEGFP-C1 (1 µg), pSC6-T7-Neo (1 µg), and increasing
amounts of pGEMT-dsEGFP (0.25 to 2 µg). Throughout transfection, the
total amount of DNA was held constant by addition of unrelated pUC19
plasmid. To test the sequence specificity of RNAi, 1 µg of the
plasmid encoding the -galactosidase, pCMV-lacZ, was used as a
control. The RLUs of fluorescence or chemiluminescence were normalized
to that of lysate containing no pGEMT-dsEGFP plasmid. The relative
activities of cells transfected with pEGFP-C1 plasmid (solid bars) and
pCMV-lacZ plasmid (open bars) are shown. Standard deviation indicates
the variation among at least five separate transfections of duplicate
samples.
|
|
Undifferentiated ES cells exhibit sequence-specific RNAi
activity.
Recently, sequence-specific RNAi has been demonstrated
in the preimplantation mouse embryo and mouse oocytes by direct
injection of dsRNA (30, 35). However, dsRNA in transgenic
blastocysts injected as zygotes produced gene silencing for only up to
six rounds of cell division (35). These results suggest
that undifferentiated cells may have RNAi activity that disappears as
the cells differentiate. Here, we investigated whether undifferentiated
ES cells respond to dsRNA for gene silencing.
Transfection of pGEMT-dsEGFP plasmid into undifferentiated ES cells
maintained on the STO feeder layer showed a sequence-specific
and
dose-dependent inhibition of EGFP expression, while

-galactosidase
expression was not affected (Fig.
4A). In
contrast, differentiated
ES cells maintained without STO feeder cells
showed nonspecific
inhibition (Fig.
4B). These cells progressively lost
refractive
boundaries and flattened to form a patch of giant
trophoblastlike
cells (data not shown), while undifferentiated ES cells
remain
as small cells packed tightly in nests (Fig.
5). Direct transfection
of the in
vitro-transcribed EGFP dsRNA, ranging from 0 to 1.0
µg, also resulted
in a dose-dependent and sequence-specific inhibition
of EGFP, shown by
the fluorescence measurement of cell lysate
(Fig.
5A) and by
fluorescence microscopy of transfected cells
(Fig.
5B). In contrast,

-galactosidase expression was not affected,
as measured by either
chemiluminescence (Fig.
5A) or histochemical
staining (Fig.
5C).

View larger version (18K):
[in this window]
[in a new window]
|
FIG. 4.
Undifferentiated ES cells exhibit RNAi activity. (A)
Sequence-specific and dose-dependent inhibition of EGFP by pGEMT-dsEGFP
plasmid in ES cells grown on a feeder layer. ES cells were plated on
STO feeder cells and transfected with three plasmids, pEGFP-C1 (1 µg), pSC6-T7-Neo (1 µg), and an increasing amount of pGEMT-dsEGFP,
ranging from 0.25 to 1 µg. To test the sequence specificity of RNAi,
1 µg of the plasmid encoding -galactosidase, pCMV-lacZ, was used
as a control. The RLUs of fluorescence or chemiluminescence were
normalized to that of lysate containing no pGEMT-dsEGFP plasmid. The
relative activities of cells transfected with pEGFP-C1 plasmid (solid
bars) and pCMV-lacZ plasmid (open bars) are shown. Standard deviation
indicates the variation among at least five separate transfection
experiments performed in duplicate. (B) Non-sequence-specific
inhibition of EGFP by pGEMT-dsEGFP plasmid in differentiated ES cells
cultured without the feeder layer. The same experiment was carried out
in ES cells plated directly on a gelatin-coated plate with no feeder
cells.
|
|

View larger version (53K):
[in this window]
[in a new window]
|
FIG. 5.
Sequence-specific and dose-dependent inhibition of EGFP
expression by in-vitro transcribed dsRNA in undifferentiated ES cells.
(A) ES cells were plated on feeder cells and transfected with 1 µg of
the pEGFP-C1 plasmid and increasing amounts, 0.25 to 1.0 µg, of the
in vitro-transcribed dsRNA. To test the sequence specificity of RNAi, 1 µg of the plasmid encoding the -galactosidase, pCMV-lacZ, was used
as a control. The RLUs of fluorescence or chemiluminescence were
normalized to that of lysate containing no dsRNA. The relative
activities of cells transfected with pEGFP-C1 plasmid (solid bars) and
pCMV-lacZ plasmid (open bars) are shown. Standard deviation indicates
the variation among at least three separate transfection performed in
duplicate. (B) Fluorescence microscopy of undifferentiated ES cells
transfected with 2.5 µg of pEGFP-C1 plasmid and an increasing amount,
0, 1, and 2 µg (lanes, 1, 2, and 3, respectively), of the in
vitro-transcribed dsRNA-EGFP. Photographs were taken 72 h later,
using a bright field (upper panel) and fluorescence (lower panel). (C)
-Galactosidase expression is not inhibited by in vitro-transcribed
dsRNA-EGFP. ES cells were transfected with 2.5 µg of pCMV-lacZ and 0, 1, or 2 µg of in vitro-transcribed dsRNA-EGFP. Histochemical staining
was carried out 72 h later.
|
|
Thus, only ES cells maintained in an undifferentiated state responded
to dsRNA for gene silencing. The sequence-specific inhibition
of dsRNA
was also shown by a decrease in EGFP mRNA but not

-galactosidase
mRNA, as measured by Northern blot analysis of ES cells transfected
under identical conditions, in which the protein activity was
measured
(Fig.
6). These results confirm
degradation of cognate
EGFP mRNA but not

-galactosidase mRNA.

View larger version (31K):
[in this window]
[in a new window]
|
FIG. 6.
Northern analysis of cognate (EGFP) and the noncognate
( -galactosidase) mRNAs. Undifferentiated ES cells were grown on the
feeder layer and transfected by three plasmids, pEGFP-C1 (1 µg),
pSC6-T7-Neo (1 µg), and an increasing amount of pGEMT-dsEGFP, 0, 1, or 2 µg (lanes 1, 2, and 3, respectively). As a control, ES cells
were transfected with three plasmids, pCMV-lacZ (1 µg), pSC6-T7-Neo
(1 µg), and an increasing amount of pGEMT-dsEGFP, 0, 1, or 2 µg
(lanes 4, 5, and 6, respectively). Total RNA was isolated from
transfected cells, and 25 µg of total RNA was loaded in each lane.
The EGFP probe was a 0.7-kb fragment isolated from the pEGFP-C1
plasmid, and the lacZ probe was a 2.5-kb fragment from
the pCMV-lacZ plasmid. The probes were labeled by
[ -32P]dCTP. A cDNA probe corresponding to the mouse
-actin coding sequence was hybridized as a control.
|
|
To investigate RNAi of an integrated gene in ES cells, we generated
several ES clones with a single copy of the EGFP gene.
We found that
dsRNA-EGFP but not dsRNA-lacZ inhibited EGFP gene
expression among
three different ES clones, as determined by fluorescence
microscopy and
FACS analysis. Transfection of dsRNA-EGFP but not
dsRNA-lacZ resulted
in a substantial decrease in fluorescence
intensity of the ES cells
(Fig.
7A). A representative FACS analysis
of one of these clones is shown in Fig.
7B. The
EGFP-positive
cells were gated, and the relative fluorescence of each
peak was
measured using the geometric mean fluorescence. EGFP
fluorescence
decreased over 70% at 48 h after transfection of 8.3 nM dsRNA-EGFP
but not by dsRNA-lacZ at the same concentration.
Following transfection
of dsRNA-EGFP, we observed a new population of
cells with reduced
fluorescence, indicated as M3 in the middle panel of
Fig.
7B.
The extent of inhibition was consistent among six independent
transfections. Because only 20 to 30% of ES cells were transfected
by
Lipofectamine 2000 (unpublished observations), the large extent
of
inhibition by dsRNA suggests that dsRNA can be delivered efficiently
to
the cytoplasm and inhibits gene expression at a low concentration
in
mammalian cells (
9).

View larger version (37K):
[in this window]
[in a new window]
|
FIG. 7.
Sequence-specific inhibition of EGFP expression by dsRNA
in the stable ES-EGFP clone, in which the EGFP gene is integrated as a
single copy. (A) Fluorescence microscopy of undifferentiated ES clone
untreated or transfected with 3 µg of in vitro-transcribed dsRNA-EGFP
or dsRNA-lacZ, respectively. Photographs were taken 72 h later,
using a bright field (upper panel) and fluorescence (lower panel). (B)
FACS analysis of the ES clone 48 h after transfection. M1
indicates the gating of GFP-negative cells, M2 the gating of
GFP-positive cells, and M3 the gating of cells with reduced
fluorescence due to RNAi. Untransfected clone (left panel; geometric
mean fluorescence: M1 = 6.12, M2= 743.15), cells transfected with
dsRNA-EGFP (middle panel; geometric mean fluorescence: M1= 6.16, M2 = 270.93), cells transfected with dsRNA-lacZ (right panel; geometric mean fluorescence: M1 = 6.43, M2= 772.95). (C) Kinetics of RNAi in undifferentiated ES-EGFP clone.
The relative geometric mean fluorescence of cells transfected with
dsRNA-EGFP (solid bars) or dsRNA-lacZ (open bars) was normalized to the
geometric mean fluorescence of untransfected cells. ES cells were split
at 72 h after the initial transfection of dsRNA and plated at
2 × 105 cells/well for the later time measurements at
100 and 124 h.
|
|
We examined the kinetics of EGFP inhibition after transfection of dsRNA
in undifferentiated ES cells. RNAi was more pronounced
at early time
points and diminished as undifferentiated ES cells
replicated,
presumably due to dilution of dsRNA per cell (Fig.
7C). Almost no
inhibition was observed 5 days after transfection.
The stability of
EGFP protein may account for the apparent lower
inhibition at 24 h
than 48 h. The dsRNA-lacZ did not show any
inhibition of EGFP
expression in all experiments, indicating specific
gene silencing
activity in undifferentiated ES cells. When the
same ES cells were
cultured without the feeder layer and LIF,
ES cells did not completely
differentiate. In this mixed population
of ES cells, dsRNA-EGFP
produced a reduction in fluorescence similar
to that observed in
undifferentiated ES cells, but dsRNA-lacZ
did
not.
The persistence of the RNAi effect in these experiments can be
explained by the presence of a mixed population of differentiated
and
undifferentiated ES cells. However, it was difficult to measure
the
extent of gene silencing in fully differentiated ES-EGFP cells,
since
their intrinsic fluorescence decreased substantially upon
differentiation. Further analysis of different clones is necessary
to
draw conclusions for RNAi for endogenous genes in differentiated
ES
cells. Taken together with the transient-transfection data
described
above, these results indicate that long dsRNA inhibited
episomal and
chromosomal target genes in undifferentiated ES cells
in a
sequence-specific
manner.
dsRNA is processed to 21 to 22 nucleotides in mammalian cells.
Small RNAs are associated with a dsRNA-dependent nuclease purified from
cultured cells (15), making it likely that such RNAs serve
as the specificity determinants in the RNAi reaction. Here, we
investigated whether such dsRNA degradation activity may reflect the
different RNAi activities among different mammalian cells. The dsRNA
degradation activity was detected by the in vitro reaction in which a
radiolabeled dsRNA was incubated with cytoplasmic extracts made from
various cell types (Fig. 8).
Drosophila S2 cells showed the highest activity, which was
saturated between 10 and 50 µg of cytoplasmic protein (data not
shown). Small RNA fragments were generated by all mammalian cell types
tested: cells with a sequence-specific RNAi (undifferentiated ES
cells), cells that showed no effect at all (CHO-K1), and cells that
showed a nonspecific decrease in gene expression (differentiated ES,
STO, and BsrT7/5 cells).

View larger version (82K):
[in this window]
[in a new window]
|
FIG. 8.
Small RNA fragments generated by
Drosophila S2 and mammalian cells. Cytoplasmic extracts
(50 µg) from various mammalian cells were incubated with 30 nmol of
radiolabeled dsRNA for 1 h at 30°C for S2 cells or 37°C for
mammalian cells. After the reaction, samples were treated with
proteinase K-0.5% SDS. The size of dsRNA was examined on a 12%
denaturing acrylamide gel. Probe indicates the radiolabeled dsRNA made
by in vitro transcription. Lane M, 10-bp markers.
|
|
 |
DISCUSSION |
Posttranscriptional gene silencing by dsRNAi is a new tool for
studying gene function in many organisms (3, 11, 26, 27,
33). However, only a few cases of RNAi have been reported in
mammalian cells (1, 30, 32, 35). Here, we investigated the
feasibility of the RNAi strategy for gene silencing in several mammalian cells by using the EGFP gene as a target, either by in situ
production of dsRNA from a transient transfection of the plasmid
harboring a 547-bp inverted repeat or by direct transfection of dsRNA
made by in vitro transcription. In both cases, the dsRNA is generated
as a hairpin structure that is resistant to RNase degradation. We
reasoned that transient transfection may produce a large amount of
stable dsRNA in the cytoplasm because it introduces a high copy number
of the plasmid in the cytoplasm, which would then be transcribed by the
T7 RNA polymerase. Using transient transfection, we show that
undifferentiated ES cells have a sequence-specific RNAi activity that
disappears as ES cells differentiate. This long dsRNA also inhibited
its cognate gene expression in undifferentiated ES cells with a single
integrated copy of the EGFP gene. Thus, both episomal and chromosomal
target genes in undifferentiated ES cells were inhibited by the long
dsRNA in a sequence-specific manner. Furthermore, the amount of dsRNA
effective for RNAi activity in undifferentiated ES cells was similar to
the amounts which caused gene silencing in Drosophila S2
cells and showed no apparent toxicity.
Several mammalian cell lines did not exhibit the sequence-specific gene
silencing by dsRNA. Two cell lines, BsrT7/5 and mouse embryonic
fibroblasts (STO), showed non-sequence-specific inhibition by dsRNA,
while CHO-K1 did not exhibit any inhibition by dsRNA on either the
cognate or noncognate gene, EGFP or lacZ. When transient cotransfection of plasmid DNA and dsRNA was carried out in several mammalian cells, 293 and NIH 3T3 cells showed no effect at all, while
BHK cells showed a nonspecific decrease in gene expression (5). RNAi has been reported in CHO cells, although the
amount of dsRNA required for interference was 2,500 times more than in Drosophila S2 cells (32). Because we tested
RNAi under identical conditions in S2 and CHO cells, the amount of
dsRNA needed to produce RNAi in the S2 cells used in our experiment may
not be sufficient to produce RNAi in CHO cells. Recently, a longer
dsRNA was shown to induce some sequence-specific silencing in addition to the nonspecific inhibition in mammalian cells (9). It
is possible that the reporter system in this study is not sensitive enough to distinguish specific RNAi from the nonspecific inhibition. In
all experiments, we detected no apparent cytotoxicity as measured by
cell numbers and morphology.
Sequence-specific RNAi has been demonstrated in the preimplantation
mouse embryo and mouse oocytes by direct injection of dsRNA (30,
35). The dsRNA in mammalian cells typically activates a protein
kinase that phosphorylates and inactivates eIF2a (16). The
ensuing inhibition of protein synthesis ultimately results in
apoptosis. This sequence-independent response may reflect a form of
primitive immune response, since the presence of dsRNA is a common
feature of many viral life cycles. Mouse oocytes, however, clearly lack
this response, as the oocytes injected with dsRNAs resume meiosis and
mature to metaphase II (30). The preimplantation mouse
embryo also lacks the response, as embryos injected with dsRNAs develop to the blastocyst stage (35).
Specific RNAi activity present in undifferentiated ES cells suggests
that undifferentiated ES cells may also lack an interferon response,
similar to mouse embryos and oocytes (30, 35). However,
RNAi activity was not permanent, since it was more pronounced at early
time points and diminished as undifferentiated ES cells replicated,
presumably due to dilution of dsRNA per cell.
Posttranscriptional gene silencing by dsRNA requires at least two
steps, conversion of the dsRNA into an active species and subsequent
targeting of the mRNA for inhibition by these sequence-specific active
species. Recent biochemical studies (2, 10, 15, 31, 36,
37) have indicated that RNAi is accomplished by a multicomponent
nuclease that targets cognate mRNA for degradation. The specificity of
this complex was derived from the incorporation of a small guide
sequence that is homologous to the mRNA substrate. These small 21- to
22-nucleotide RNAs, originally identified in plants with active RNAi
(14), have also been observed in Drosophila embryos (10, 36, 37) and S2 cells (2, 15). We
investigated whether such dsRNA degradation activity may reflect the
different RNAi activities among different mammalian cells.
Although Drosophila S2 cells showed the most prominent
product of 21 to 22 bp, all mammalian cells tested produced distinct RNA products of the same size. Thus, mammalian cells have the ability
to generate 21- to 22-nucleotide fragments from long dsRNA regardless
of their apparent RNAi activity. While our manuscript was being
reviewed, Tuschl's group reported that 21-nucleotide short interfering
RNA (siRNA) was capable of gene silencing in several mammalian cells in
which longer dsRNA failed to produce RNAi (9). The
apparent lack of RNAi by longer dsRNA in mammalian cells was attributed
to nonspecific activation of the interferon response by dsRNA longer
than 30 bp, masking the specific RNAi. Therefore, our findings that
mammalian cells can generate siRNA regardless of their apparent RNAi
activity provide an insight in gene silencing of mammalian cells by
siRNA. It would be interesting to compare the extent of gene silencing
by siRNA and longer dsRNA in cells that do not show nonspecific inhibition.
ES cells and other stem cells are valuable tools for the study of cell
and tissue differentiation and for the creation of animal models of
disease. These findings offer an opportunity to use dsRNAi for
inhibition of gene expression in ES cells to study differentiation.
Stem cells also have the potential for therapeutic use, including the
development of replacement tissues if regulation of their
differentiation can be understood. The results presented here
indicate that RNAi can be used to inhibit gene expression in
mouse ES cells and thus may be a useful approach for investigations of
stem cell biology in general.
 |
ACKNOWLEDGMENTS |
We are grateful to Olga Igoucheva for in vitro RNA degradation
study and discussion, Romaica Omaruddin and Haiching Ma for assistance
with ES cell culture, Gregory Hannon for Drosophila cells and plasmids, and Scott Diamond for M9 peptides. We thank Tom
Tuschl and John Klement for discussion and critical reading of the manuscript.
This work was supported in part by grants from the National Institutes
of Health (GM61942, AR38923, and AR44350) to K.Y. and EY12910, the
Rosanne H. Silbermann Foundation, and Research to Prevent Blindness to
E.A.P.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Department of
Dermatology and Cutaneous Biology, Department of Biochemistry and
Molecular Pharmacology, Jefferson Institute of Molecular Medicine,
Thomas Jefferson University, and Jefferson Medical College, 233 South 10th Street, Philadelphia, PA 19107. Phone: (215) 503-5434. Fax: (215)
503-5788. E-mail: kyonggeun.yoon{at}mail.tju.edu.
 |
REFERENCES |
| 1.
|
Bahramian, M. B., and H. Zarbl.
1999.
Transcriptional and posttranscriptional silencing of rodent 1(I) collagen by a homologous transcriptionally self-silenced transgene.
Mol. Cell. Biol.
19:274-283[Abstract/Free Full Text].
|
| 2.
|
Bernstein, E.,
A. A. Caudy,
S. M. Hammond, and G. J. Hannon.
2001.
Role for a bidentate ribonuclease in the initiation step of RNA interference.
Nature
409:363-366[CrossRef][Medline].
|
| 3.
|
Bosher, J. M., and M. Labouesse.
2000.
RNA interference: genetic wand and genetic watchdog.
Nat. Cell Biol.
2:E31-E36[CrossRef][Medline].
|
| 4.
|
Buchholz, U. J.,
S. Finke, and K. K. Conzelmann.
1999.
Generation of bovine respiratory syncytial virus (BRSV) from cDNA: BRSV NS2 is not essential for virus replication in tissue culture, and the human RSV leader region acts as a functional BRSV genome promoter.
J. Virol
73:251-259[Abstract/Free Full Text].
|
| 5.
|
Caplen, N. J.,
J. Fleenor,
A. Fire, and R. A. Morgan.
2000.
dsRNA-mediated gene silencing in cultured Drosophila cells: a tissue culture model for the analysis of RNA interference.
Gene
252:95-105[CrossRef][Medline].
|
| 6.
|
Catalanotto, C.,
G. Azzalin,
G. Macino, and C. Cogoni.
2000.
Gene silencing in worms and fungi.
Nature
404:245[CrossRef][Medline].
|
| 7.
|
Clemens, J. C.,
C. A. Worby,
N. Simonson-Leff,
M. Muda,
T. Maehama,
B. A. Hemmings, and J. E. Dixon.
2000.
Use of double-stranded RNA interference in Drosophila cell lines to dissect signal transduction pathways.
Proc. Natl. Acad. Sci. USA
97:6499-6503[Abstract/Free Full Text].
|
| 8.
|
Dignam, J. D.,
R. M. Lebovitz, and R. G. Roeder.
1983.
Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei.
Nucleic Acids Res.
11:1475-1489[Abstract/Free Full Text].
|
| 9.
|
Elbashir, S. M.,
J. Harborth,
W. Lendeckel,
A. Yalcin,
K. Weber, and T. Tuschl.
2001.
Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells.
Nature
411:494-498[CrossRef][Medline].
|
| 10.
|
Elbashir, S. M.,
W. Lendeckel, and T. Tuschl.
2001.
RNA interference is mediated by 21- and 22-nucleotide RNAs.
Genes Dev.
15:188-200[Abstract/Free Full Text].
|
| 11.
|
Fire, A.
1999.
RNA-triggered gene silencing.
Trends Genet.
15:358-363[CrossRef][Medline].
|
| 12.
|
Fire, A.,
S. Xu,
M. K. Montgomery,
S. A. Kostas,
S. E. Driver, and C. C. Mello.
1998.
Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans.
Nature
391:806-811[CrossRef][Medline].
|
| 13.
|
Grant, C. E.,
M. Z. Vasa, and R. G. Deeley.
1995.
cIRF-3, a new member of the interferon regulatory factor (IRF) family that is rapidly and transiently induced by dsRNA.
Nucleic Acids Res.
23:2137-2146[Abstract/Free Full Text].
|
| 14.
|
Hamilton, A. J., and D. C. Baulcombe.
1999.
A species of small antisense RNA in posttranscriptional gene silencing in plants.
Science
286:950-952[Abstract/Free Full Text].
|
| 15.
|
Hammond, S. M.,
E. Bernstein,
D. Beach, and G. J. Hannon.
2000.
An RNA-directed nuclease mediates posttranscriptional gene silencing in Drosophila cells.
Nature
404:293-296[CrossRef][Medline].
|
| 16.
|
Kaufman, R. J.
1999.
Double-stranded RNA-activated protein kinase mediates virus-induced apoptosis: a new role for an old actor.
Proc. Natl. Acad. Sci. USA
96:11693-11695[Free Full Text].
|
| 17.
|
Kennerdell, J. R., and R. W. Carthew.
1998.
Use of dsRNA-mediated genetic interference to demonstrate that frizzled and frizzled 2 act in the wingless pathway.
Cell
95:1017-1026[CrossRef][Medline].
|
| 18.
|
Ketting, R. F.,
T. H. Haverkamp,
H. G. van Luenen, and R. H. Plasterk.
1999.
Mut-7 of C. elegans, required for transposon silencing and RNA interference, is a homolog of Werner syndrome helicase and RNase D.
Cell
99:133-141[CrossRef][Medline].
|
| 19.
|
Ketting, R. F., and R. H. Plasterk.
2000.
A genetic link between cosuppression and RNA interference in C. elegans.
Nature
404:296-298[CrossRef][Medline].
|
| 20.
|
Malinsky, S.,
A. Bucheton, and I. Busseau.
2000.
New insights on homology-dependent silencing of I factor activity by transgenes containing ORF1 in Drosophila melanogaster.
Genetics
156:1147-1155[Abstract/Free Full Text].
|
| 21.
|
Meins, F., Jr.
2000.
RNA degradation and models for posttranscriptional gene-silencing.
Plant Mol. Biol
43:261-273[CrossRef][Medline].
|
| 22.
|
Mette, M. F.,
W. Aufsatz,
J. van der Winden,
M. A. Matzke, and A. J. Matzke.
2000.
Transcriptional silencing and promoter methylation triggered by double-stranded RNA.
EMBO J.
19:5194-5201[CrossRef][Medline].
|
| 23.
|
Muskens, M. W.,
A. P. Vissers,
J. N. Mol, and J. M. Kooter.
2000.
Role of inverted DNA repeats in transcriptional and posttranscriptional gene silencing.
Plant Mol. Biol.
43:243-260[CrossRef][Medline].
|
| 24.
|
Parrish, S.,
J. Fleenor,
S. Xu,
C. Mello, and A. Fire.
2000.
Functional anatomy of a dsRNA trigger: differential requirement for the two trigger strands in RNA interference.
Mol. Cell
6:1077-1087[CrossRef][Medline].
|
| 25.
|
Radecke, F.,
P. Spielhofer,
H. Schneider,
K. Kaelin,
M. Huber,
C. Dotsch,
G. Christiansen, and M. A. Billeter.
1995.
Rescue of measles viruses from cloned DNA.
EMBO J.
14:5773-5784[Medline].
|
| 26.
|
Sharp, P. A.
2001.
RNA interference 2001.
Genes Dev.
15:485-490[Free Full Text].
|
| 27.
|
Sharp, P. A., and P. D. Zamore.
2000.
Molecular biology: RNA interference.
Science
287:2431-2433[Free Full Text].
|
| 28.
|
Smardon, A.,
J. M. Spoerke,
S. C. Stacey,
M. E. Klein,
N. Mackin, and E. M. Maine.
2000.
EGO-1 is related to RNA-directed RNA polymerase and functions in germ-line development and RNA interference in C. elegans.
Curr. Biol.
10:169-178[CrossRef][Medline].
|
| 29.
| Stam, M., R. de Bruin, R. van R. Blokland. A. van der
Hoorn, J. N. Mol, and J. M. Kooter. 2000. Distinct
features of posttranscriptional gene silencing by antisense transgenes
in single copy and inverted T-DNA repeat loci. Plant J. 21:27-42.
|
| 30.
|
Svoboda, P.,
P. Stein,
H. Hayashi, and R. M. Schultz.
2000.
Selective reduction of dormant maternal mRNAs in mouse oocytes by RNA interference.
Development
127:4147-4156[Abstract].
|
| 31.
|
Tuschl, T.,
P. D. Zamore,
R. Lehmann,
D. P. Bartel, and P. A. Sharp.
1999.
Targeted mRNA degradation by double-stranded RNA in vitro.
Genes Dev.
13:3191-3197[Abstract/Free Full Text].
|
| 32.
|
Ui-Tei, K.,
S. Zenno,
Y. Miyata, and K. Saigo.
2000.
Sensitive assay of RNA interference in Drosophila and Chinese hamster cultured cells using firefly luciferase gene as target.
FEBS Lett.
479:79-82[CrossRef][Medline].
|
| 33.
|
Vaucheret, H., and M. Fagard.
2001.
Transcriptional gene silencing in plants: targets, inducers and regulators.
Trends Genet.
17:29-35[CrossRef][Medline].
|
| 34.
|
Wargelius, A.,
S. Ellingsen, and A. Fjose.
1999.
Double-stranded RNA induces specific developmental defects in zebrafish embryos.
Biochem. Biophys. Res. Commun.
263:156-161[CrossRef][Medline].
|
| 35.
|
Wianny, F., and M. Zernicka-Goetz.
2000.
Specific interference with gene function by double-stranded RNA in early mouse development.
Nat. Cell Biol.
2:70-75[CrossRef][Medline].
|
| 36.
|
Yang, D.,
H. Lu, and J. W. Erickson.
2000.
Evidence that processed small dsRNAs may mediate sequence-specific mRNA degradation during RNAi in Drosophila embryos.
Curr. Biol.
10:1191-1200[CrossRef][Medline].
|
| 37.
|
Zamore, P. D.,
T. Tuschl,
P. A. Sharp, and D. P. Bartel.
2000.
RNAi: double-stranded RNA directs the ATP-dependent cleavage of mRNA at 21 to 23 nucleotide intervals.
Cell
101:25-33[CrossRef][Medline].
|
Molecular and Cellular Biology, November 2001, p. 7807-7816, Vol. 21, No. 22
0270-7306/01/$04.00+0 DOI: 10.1128/MCB.21.22.7807-7816.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Olejniczak, M., Galka, P., Krzyzosiak, W. J.
(2009). Sequence-non-specific effects of RNA interference triggers and microRNA regulators. Nucleic Acids Res
0: gkp829v1-gkp829
[Abstract]
[Full Text]
-
Umbach, J. L., Cullen, B. R.
(2009). The role of RNAi and microRNAs in animal virus replication and antiviral immunity. Genes Dev.
23: 1151-1164
[Abstract]
[Full Text]
-
Svoboda, P., Stein, P.
(2009). RNAi Experiments in Mouse Oocytes and Early Embryos. CSH Protocols
2009: pdb.top56-pdb.top56
[Abstract]
[Full Text]
-
Babiarz, J. E., Ruby, J. G., Wang, Y., Bartel, D. P., Blelloch, R.
(2008). Mouse ES cells express endogenous shRNAs, siRNAs, and other Microprocessor-independent, Dicer-dependent small RNAs. Genes Dev.
22: 2773-2785
[Abstract]
[Full Text]
-
Dinger, M. E, Mercer, T. R, Mattick, J. S
(2008). RNAs as extracellular signaling molecules. J Mol Endocrinol
40: 151-159
[Abstract]
[Full Text]
-
Xu, Y., Mirmalek-Sani, S.-H., Lin, F., Zhang, J., Oreffo, R. O.C.
(2007). Adipocyte differentiation induced using nonspecific siRNA controls in cultured human mesenchymal stem cells. RNA
13: 1179-1183
[Abstract]
[Full Text]
-
Murchison, E. P., Partridge, J. F., Tam, O. H., Cheloufi, S., Hannon, G. J.
(2005). Characterization of Dicer-deficient murine embryonic stem cells. Proc. Natl. Acad. Sci. USA
102: 12135-12140
[Abstract]
[Full Text]
-
Yan, W., Ma, L., Stein, P., Pangas, S. A., Burns, K. H., Bai, Y., Schultz, R. M., Matzuk, M. M.
(2005). Mice Deficient in Oocyte-Specific Oligoadenylate Synthetase-Like Protein OAS1D Display Reduced Fertility. Mol. Cell. Biol.
25: 4615-4624
[Abstract]
[Full Text]
-
Zhou, H., Xia, X. G., Xu, Z.
(2005). An RNA polymerase II construct synthesizes short-hairpin RNA with a quantitative indicator and mediates highly efficient RNAi. Nucleic Acids Res
33: e62-e62
[Abstract]
[Full Text]
-
Wobus, A. M., Boheler, K. R.
(2005). Embryonic Stem Cells: Prospects for Developmental Biology and Cell Therapy. Physiol. Rev.
85: 635-678
[Abstract]
[Full Text]
-
O'Shea, K. S.
(2004). Self-renewal vs. Differentiation of Mouse Embryonic Stem Cells. Biol. Reprod.
71: 1755-1765
[Abstract]
[Full Text]
-
Wang, Q., Carmichael, G. G.
(2004). Effects of Length and Location on the Cellular Response to Double-Stranded RNA. Microbiol. Mol. Biol. Rev.
68: 432-452
[Abstract]
[Full Text]
-
Szabo, P. E., Tang, S.-H. E., Silva, F. J., Tsark, W. M. K., Mann, J. R.
(2004). Role of CTCF Binding Sites in the Igf2/H19 Imprinting Control Region. Mol. Cell. Biol.
24: 4791-4800
[Abstract]
[Full Text]
-
Kariko, K., Bhuyan, P., Capodici, J., Weissman, D.
(2004). Small Interfering RNAs Mediate Sequence-Independent Gene Suppression and Induce Immune Activation by Signaling through Toll-Like Receptor 3. J. Immunol.
172: 6545-6549
[Abstract]
[Full Text]
-
Yang, S., Cho, Y. S., Chennathukuzhi, V. M., Underkoffler, L. A., Loomes, K., Hecht, N. B.
(2004). Translin-associated Factor X Is Post-transcriptionally Regulated by Its Partner Protein TB-RBP, and Both Are Essential for Normal Cell Proliferation. J. Biol. Chem.
279: 12605-12614
[Abstract]
[Full Text]
-
Ui-Tei, K., Naito, Y., Takahashi, F., Haraguchi, T., Ohki-Hamazaki, H., Juni, A., Ueda, R., Saigo, K.
(2004). Guidelines for the selection of highly effective siRNA sequences for mammalian and chick RNA interference. Nucleic Acids Res
32: 936-948
[Abstract]
[Full Text]
-
Milhavet, O., Gary, D. S., Mattson, M. P.
(2003). RNA Interference in Biology and Medicine. Pharmacol. Rev.
55: 629-648
[Abstract]
[Full Text]
-
Einav, Y., Shistik, E., Shenfeld, M., Simons, A. H., Melton, D. W., Canaani, D.
(2003). Replication and episomal maintenance of Epstein-Barr virus-based vectors in mouse embryonal fibroblasts enable synthetic lethality screens. Molecular Cancer Therapeutics
2: 1121-1128
[Abstract]
[Full Text]
-
Opalinska, J. B., Gewirtz, A. M.
(2003). Therapeutic Potential of Antisense Nucleic Acid Molecules. Sci Signal
2003: pe47-pe47
[Abstract]
[Full Text]
-
SAUNDERS, L. R., BARBER, G. N.
(2003). The dsRNA binding protein family: critical roles, diverse cellular functions. FASEB J.
17: 961-983
[Abstract]
[Full Text]
-
Hemmings-Mieszczak, M., Dorn, G., Natt, F. J., Hall, J., Wishart, W. L.
(2003). Independent combinatorial effect of antisense oligonucleotides and RNAi-mediated specific inhibition of the recombinant Rat P2X3 receptor. Nucleic Acids Res
31: 2117-2126
[Abstract]
[Full Text]
-
Kosciolek, B. A., Kalantidis, K., Tabler, M., Rowley, P. T.
(2003). Inhibition of Telomerase Activity in Human Cancer Cells by RNA Interference. Molecular Cancer Therapeutics
2: 209-216
[Abstract]
[Full Text]
-
Capodici, J., Kariko, K., Weissman, D.
(2002). Inhibition of HIV-1 Infection by Small Interfering RNA-Mediated RNA Interference. J. Immunol.
169: 5196-5201
[Abstract]
[Full Text]
-
Yang, D., Buchholz, F., Huang, Z., Goga, A., Chen, C.-Y., Brodsky, F. M., Bishop, J. M.
(2002). Short RNA duplexes produced by hydrolysis with Escherichia coli RNase III mediate effective RNA interference in mammalian cells. Proc. Natl. Acad. Sci. USA
99: 9942-9947
[Abstract]
[Full Text]
-
Tuschl, T., Borkhardt, A.
(2002). Small Interfering RNAs: A Revolutionary Tool for the Analysis of Gene Function and Gene Therapy. Mol. Interv.
2: 158-167
[Abstract]
[Full Text]
-
Yu, J.-Y., DeRuiter, S. L., Turner, D. L.
(2002). RNA interference by expression of short-interfering RNAs and hairpin RNAs in mammalian cells. Proc. Natl. Acad. Sci. USA
99: 6047-6052
[Abstract]
[Full Text]
-
Paddison, P. J., Caudy, A. A., Bernstein, E., Hannon, G. J., Conklin, D. S.
(2002). Short hairpin RNAs (shRNAs) induce sequence-specific silencing in mammalian cells. Genes Dev.
16: 948-958
[Abstract]
[Full Text]
-
Zhou, Y., Ching, Y.-P., Kok, K. H., Kung, H.-f., Jin, D.-Y.
(2002). Post-transcriptional suppression of gene expression in Xenopus embryos by small interfering RNA. Nucleic Acids Res
30: 1664-1669
[Abstract]
[Full Text]
-
Yu, J.-Y., DeRuiter, S. L., Turner, D. L.
(2002). RNA interference by expression of short-interfering RNAs and hairpin RNAs in mammalian cells. Proc. Natl. Acad. Sci. USA
99: 6047-6052
[Abstract]
[Full Text]